利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.015 秒)

    Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
    1.
    发明申请
    Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis 有权
    用于闪烁扫描的特异性结合分子，含有它们的缀合物和用于治疗血管发生的治疗方法

    公开(公告)号：US20060133994A1

    公开(公告)日：2006-06-22

    申请号：US10821930

    申请日：2004-04-12

    申请人： Dario Neri ,  Lorenzo Tarli ,  Francesca Viti ,  Manfred Birchler

    发明人： Dario Neri ,  Lorenzo Tarli ,  Francesca Viti ,  Manfred Birchler

    IPC分类号： A61K51/00 ,  A61K39/395 ,  C07K16/18

    CPC分类号： C07C63/04 ,  A61K51/1018 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/622

    摘要： The present invention relates to antibodies with sub-nanomolar affinity specific for a characteristic epitope of the ED-B domain of fibronectin, a marker of angiogenesis. Furthermore, it relates to the use of radiolabelled high affinity anti ED-B antibodies for detecting new-forming blood vessels in vivo and a diagnostic kit comprising comprising said antibody. Furthermore, it relates to conjugates comprising said antibodies and a suitable photoactive molecules (e.g. an appropriately chosen photosensitizer or radionuclide), and their use for the selective light-mediated occlusion of new blood vessels.

    摘要翻译： 本发明涉及对纤连蛋白的ED-B结构域的特征性表位具有亚纳摩尔亲和力的抗体，血管发生的标志物。 此外，它涉及放射性标记的高亲和力抗ED-B抗体用于检测体内新形成血管的用途，以及包含所述抗体的诊断试剂盒。 此外，它涉及包含所述抗体和合适的光活性分子（例如适当选择的光敏剂或放射性核素）的缀合物，以及它们用于选择性光介导的新血管阻塞的用途。

    Adjuvanting meningococcal factor H binding protein
    3.
    发明授权
    Adjuvanting meningococcal factor H binding protein 有权
    补充脑膜炎球菌因子H结合蛋白

    公开(公告)号：US08398988B2

    公开(公告)日：2013-03-19

    申请号：US13403865

    申请日：2012-02-23

    申请人： Mario Contorni ,  Lorenzo Tarli

    发明人： Mario Contorni ,  Lorenzo Tarli

    IPC分类号： A61K39/00 ,  A61K39/02 ,  A61K39/095 ,  A61K39/385

    CPC分类号： A61K39/095 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/6018 ,  A61K2039/70

    摘要： Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminum hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminum hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminum hydroxyphosphate adjuvant.

    摘要翻译： 已经提出因子H结合蛋白（fHBP）用于免疫血清群B脑膜炎球菌（MenB）。 （i）确保在等于或低于佐剂点零点（PZC）的pH下进行吸附，和/或（ii）选择fHBP和佐剂，可以有效地将该抗原吸附到羟基磷酸铝佐剂上 等电点/ PZC在5.0至7范围内，和/或（iii）选择具有等电点高于佐剂PZC的fHBP，并使用缓冲液使pH达到PZC的1.2pH单位内。 该吸附对于包含多种fHBP变体的组合物以及在应避免使用氢氧化铝佐剂的情况下特别有用。 缓冲的药物组合物可以包括至少两种不同的脑膜炎球菌fHBP抗原，两者都至少85％被羟基磷酸羟丙酯佐剂吸附。

    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN
    5.
    发明申请
    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN 有权

    公开(公告)号：US20120148619A1

    公开(公告)日：2012-06-14

    申请号：US13403865

    申请日：2012-02-23

    申请人： Mario CONTORNI ,  Lorenzo Tarli

    发明人： Mario CONTORNI ,  Lorenzo Tarli

    IPC分类号： A61K39/095 ,  A61P37/04 ,  A61P31/04 ,  A61K39/385

    CPC分类号： A61K39/095 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/6018 ,  A61K2039/70

    摘要： Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

    摘要翻译： 已经提出因子H结合蛋白（fHBP）用于免疫血清群B脑膜炎球菌（'MenB'）。 （i）确保在等于或低于佐剂点零点（PZC）的pH下进行吸附，和/或（ii）选择fHBP和佐剂，可以有效地将该抗原吸附到羟基磷酸铝佐剂上 等电点/ PZC在5.0至7范围内，和/或（iii）选择具有等电点高于佐剂PZC的fHBP，并使用缓冲液使pH达到PZC的1.2pH单位内。 该吸附对于包含多种fHBP变体的组合物以及在应避免使用氢氧化铝佐剂的情况下特别有用。 缓冲的药物组合物可以包括至少两种不同的脑膜炎球菌fHBP抗原，两者都至少85％被羟基磷酸羟丙酯佐剂吸附。

    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN
    6.
    发明申请
    ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN 审中-公开

    公开(公告)号：US20120070458A1

    公开(公告)日：2012-03-22

    申请号：US13260534

    申请日：2010-03-24

    申请人： Mario Contorni ,  Lorenzo Tarli

    发明人： Mario Contorni ,  Lorenzo Tarli

    IPC分类号： A61K39/095 ,  A61P31/04 ,  A61K39/385

    CPC分类号： A61K39/095 ,  A61K47/02 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/6018 ,  A61K2039/70

    摘要： Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.